The Justice Department said CVS Pharmacy and related entities agreed to pay $315 million to resolve allegations of unlawfully filling controlled-substance prescriptions and seeking federal reimbursement from October 2013 through December 2025. The agreement includes added dispensing safeguards. The government said the claims are allegations only, with no liability determination.
CVS Pharmacy Inc., a Rhode Island-based pharmacy chain, and its related corporate entities (collectively, CVS) have agreed to pay $315 million to resolve allegations that, from October 17, 2013 through December 2, 2025, CVS illegally filled prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act (CSA), and then sought payment for many of those invalid prescriptions from Medicare and other federal healthcare programs in violation of the False Claims Act (FCA).
A jury found Omnicare liable for more than three million false claims and CVS Health liable for causing some claims. A judge later ordered $948.8 million in a related Omnicare case; reporting said CVS was jointly liable for part of the penalties and planned to appeal. CVS disputed the case’s characterization and said no patient was harmed.
False claims in the healthcare industry cost every American. Today, a unanimous jury found Omnicare, the country’s largest long-term care pharmacy, liable for fraudulently dispensing drugs without valid prescriptions to elderly and disabled people in assisted living facilities and other residential long-term care facilities. After a four-week trial, the jury found that Omnicare billed Medicare, Medicaid, and TRICARE for over three million false claims resulting in $135,592,814 in damages. Under the federal False Claims Act, the Government is entitled to three times the amount of these assessed damages, or $406,778,442, plus statutory penalties to be determined by the Court. This is one of the largest damages verdicts rendered by a jury in a False Claims Act case. The jury also found CVS Health Corporation, Omnicare’s parent, liable for causing Omnicare to submit false claims. I thank the women and men of our Civil Division for continuing to pursue those who seek to exploit the healthcare system. I also thank the U.S. Department of Health and Human Services and the Department of Defense for their support and assistance throughout this case.
Uri Bassan, a former Omnicare pharmacist in Albuquerque, N.M., first filed the suit in 2015. The US Department of Justice joined the suit in 2019. Both parties accused Omnicare of improperly billing Medicare, Medicaid, and Tricare prescriptions for patients in assisted-living communities, group homes, and other long-term care facilities without valid prescriptions.
Last month, a Manhattan federal judge ordered CVS' Omnicare unit to pay $948.8 million in a separate whistleblower lawsuit alleging fraudulent billing. CVS plans to appeal that judgment.
Omnicare allegedly assigned new prescription numbers without necessary paperwork and pharmacist approvals, after the original prescriptions expired or ran out of refills.
On Aug. 20, 2025, a federal judge ordered CVS Health’s pharmacy benefit manager, CVS Caremark, to pay $289.9 million in damages and penalties for overcharging Medicare for prescription drugs. The judge said the overbilling lasted two years and described the conduct as financially motivated. CVS said it plans to appeal.
Aug 20 (Reuters) - A federal judge ordered CVS Health's (CVS.N), opens new tab pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it overcharged Medicare for prescription drugs.
On Aug. 18, 2025, the Delaware Supreme Court ruled for insurer units of AIG and Chubb, finding opioid-related suits against CVS did not seek damages for specific, individualized bodily injury and therefore did not qualify for coverage. CVS had argued its 2022 multibillion-dollar settlement supported coverage; the court rejected that argument.
The state’s high court rejected, among other things, CVS’ argument that its roughly $5 billion, 10-year national settlement with states and cities over opioid claims announced in 2022 demonstrates the company had been sued because of bodily injury.
CVS Health Corp. is entitled to insurance coverage for litigation alleging it fueled the opioid crisis, despite a landmark 2022 decision siding with insurers over Rite Aid Corp. on opioid-related litigation, CVS told the Delaware Supreme Court.
CVS Health executive Tilak Mandadi said AI could improve healthcare experiences and help care teams, citing tools that cut nurse practitioners’ call-preparation time from 40% to 5% and summarize calls. He said AI should support, not replace, human interaction and that qualified people—not AI—would make decisions affecting health outcomes.
The number one item is, how do we transform health care experience? Good experience leads to people engaging in their own health better and more. People engaging in their own health leads to trust in health care and doctors. Trust leads to behavioral change in how people view their lives, and this behavioral change is conclusively proven to lead to better health outcomes and longevity.
"This is health care's opportunity to really leapfrog," says Tilak Mandadi, executive vice president of ventures and chief experience and technology officer at CVS Health.
In May 2020, CVS Health subsidiary Omnicare agreed to pay a $15.3 million civil penalty and increase audits and monitoring of nursing-home emergency medication kits. The U.S. alleged it allowed controlled drugs to be dispensed without valid prescriptions; Omnicare did not admit liability, and the settlement resolved the allegations.
LOS ANGELES – Omnicare, Inc., a subsidiary of CVS Health and a provider of pharmacy services to long-term care facilities, has agreed to pay the United States a $15.3 million civil penalty to resolve allegations that it violated federal law by, among other things, allowing opioids and other controlled substances to be dispensed without a valid prescription, United States Attorney Nicola T. Hanna announced today.
On December 2, 2025, the U.S. Attorney’s Office announced CVS Pharmacy agreed to pay $37.76 million to resolve allegations that it improperly billed government health programs for premature insulin-pen refills between 2010 and 2020. CVS admitted that pharmacies sometimes reported inaccurate supply data and dispensed more insulin than beneficiaries needed.
To fill insulin prescriptions as quickly as possible and to ensure that reimbursement claims for insulin pens were not rejected, CVS instructed its pharmacy staff simply to report the maximum days-of-supply allowed under the beneficiary’s plan when dispensing full insulin pen cartons, which was often lower than the actual days-of-supply dispensed. Many CVS pharmacies did not internally document and use the actual days-of-supply dispensed to determine when patients could next refill their prescription. To the contrary, CVS’ dispensing software calculated refill dates automatically based on inaccurate days-of-supply data reported to the PBM. As a result, CVS pharmacy staff repeatedly refilled prescriptions prematurely, dispensing substantially more insulin to GHP beneficiaries than they actually needed and substantially sooner than they needed it according to their prescriptions. As a result, some GHP beneficiaries accumulated large quantities of unused insulin, which was both wasteful and potentially dangerous as insulin can expire.
The Intercept reported in April 2021 that CVS Health gave $5 million to the Partnership for America’s Health Care Future, which advocates against proposals including Medicare for All and a public option. CVS CEO Karen Lynch also signed a letter warning Connecticut’s governor that a public option could drive insurers from the state. Neither CVS nor the group commented.
In a year marked by a coronavirus pandemic that has killed millions, CVS Health financed a wave of political advocacy against measures to control health care costs and increase access.
In 2013, CVS Pharmacy and Oklahoma CVS Pharmacy agreed to pay the U.S. government $11 million to settle civil claims alleging Controlled Substances Act recordkeeping violations at pharmacies from 2005 to 2011. CVS did not admit liability, and the government did not concede the claims lacked merit.
1) Creating, entering and maintaining invalid "dummy" DEA registration numbers or numbers other than the valid DEA registration number of the prescribing practitioner on dispensing records, which were at times provided to state prescription drug monitoring programs;
A House Judiciary Committee report said CVS may have violated antitrust laws by using network rules to deter independent pharmacies from working with outside medication hubs; CVS called the report misleading and said it was addressing potential waste and fraud. Separately, the FTC announced a proposed Caremark settlement requiring business-practice changes and barring unfair interference with hub services.
A House committee found that CVS Health may have violated federal antitrust laws by threatening independent pharmacies to keep them from using money-saving services outside the company’s pharmacy benefit manager (PBM) network. The House Judiciary Committee, led by Chair Jim Jordan (R-Ohio), opened an investigation into possible anticompetitive practices by the company’s PBM, CVS Caremark, in December 2024, seeking to examine the company’s relationship with pharmaceutical hubs, third-party online services designed to streamline patient access to complex specialty medication and increase price transparency. In the report released Wednesday, the committee said that internal documents showed CVS leveraged its pharmacy network contracts to stifle competition by learning how the hub models operate, then changing its rules to prevent independent pharmacies from working with hubs. “In 2019, CVS Health developed a plan to invest heavily in the digital pharmacy sector after facing intense competition from the likes of PillPack, Phil, and Blink. CVS Health saw online pharmacy services as the future and feared falling behind in the market if it did not develop its own hub pharmacy to compete against outside hubs like Blink,” the report states. "After surveilling competing rival hubs and investigating independent pharmacies that work with those hubs, CVS Health began taking aggressive action to eliminate any outside competition,” it continued. "It is possible that CVS Health’s conduct violated the antitrust laws," the report concludes. A spokesperson for CVS called the report “misguided, misleading and inaccurate” in a statement to The Hill on Wednesday. “CVS Caremark works to make prescription drugs more affordable in the United States, while ridding the pharmaceutical supply chain of potential fraud, waste, and abuse (FWA),” said David Whitrap, the company’s vice president of communications. CVS initially justified its actions by claiming it was trying to stop fraud within the hub system, but it provided no evidence to support those allegations, according to the report. "CVS harassed pharmacies and small innovative technology companies," a Judiciary committee spokesperson said in a statement on Wednesday night. "After more than a year of investigation and repeated requests, CVS has failed to point to a single instance of fraud justifying their actions." "If these hubs were so fraudulent, why did CVS change its policies only after being exposed?" the spokesperson added. The report indicates that the company then claimed it was working to remove hyperinflated drugs from its formulary to reduce
Caremark Rx LLC and Zinc Health Services LLC (collectively Caremark) have agreed to a settlement agreement that requires the PBM to adopt changes to its business practices to drive down patients’ out-of-pocket costs, increase transparency and ensure community pharmacies are treated fairly.
CVS Health, Caremark Rx and nine PBM subsidiaries agreed to pay $2 million to resolve allegations that, while administering client benefits, they improperly rejected, denied or reduced pharmacy claims for Medicaid, VA, Indian Health Services and military health beneficiaries also eligible under CVS-administered programs. HHS OIG lists the action date as December 22, 2016.
After it disclosed conduct to OIG pursuant to its CIA, CVS Health Corporation, Caremark Rx, LLC, and nine of its pharmacy benefit management subsidiaries (collectively, "CVS"), headquartered in Rhode Island, agreed to pay $2,000,000 to resolve allegations that CVS, acting as the Pharmacy Benefit Manager for its clients, improperly rejected, denied, or reduced pharmacy payments on claims by state Medicaid, Veterans Affairs, Indian Health Services, and Military Health System programs for beneficiaries of these programs where the beneficiaries were also eligible for benefits under CVS's administered programs.
In May 2015, CVS Health agreed to pay $22 million to resolve allegations that two Sanford, Florida, stores dispensed controlled substances on prescriptions not issued for legitimate medical purposes. CVS acknowledged its pharmacies’ dispensing responsibilities and that certain stores’ practices were not fully consistent with compliance obligations. The stores’ DEA licenses had been revoked in 2012.
Orlando, FL – United States Attorney A. Lee Bentley, III announces today that CVS Health has agreed to pay $22 million to resolve allegations that two of its retail stores in the City of Sanford distributed controlled substances based on prescriptions that had not been issued for legitimate medical purposes by a health care provider acting in the usual course of professional practice. CVS acknowledged that its retail pharmacies had a responsibility to dispense only those prescriptions that were issued based on legitimate medical need. CVS further acknowledged that certain of its retail stores dispensed certain controlled substances in a manner not fully consistent with their compliance obligations under the Controlled Substances Act and the related regulations.
In a March 17, 2026 letter published March 21, CVS Health CEO and chairman J. David Joyner asked Tennessee lawmakers to oppose SB2040/HB1959. He said the bill would force CVS to close its home-delivery and specialty operations and 134 community pharmacies, disrupting patient care; CVS cited more than 6,000 Tennessee employees and $4.2 billion in economic impact.
CVS Health's CEO urges Tennessee lawmakers to oppose bill SB2040/HB1959.
In October 2018, the U.S. Department of Justice and five states sued to block CVS Health’s proposed $69 billion acquisition of Aetna, alleging it would substantially lessen competition for individual Medicare Part D plans in 16 regions and lead to higher costs and lower service quality. The parties proposed a settlement requiring CVS and Aetna to divest Aetna’s individual-plan business to WellCare; the settlement was proposed, not a final finding
On December 3, 2017, CVS agreed to acquire Aetna for approximately $69 billion. This acquisition is the subject of the Complaint and proposed Final Judgment filed by the United States on October 10, 2018. The proposed transaction would lessen competition substantially in markets for the sale of individual PDPs. In recognition of the significant competitive concerns raised by the proposed merger, Defendants have agreed to divest Aetna's individual PDP business.
32. CVS and Aetna have sought to win individual PDP customers in various ways. For example, CVS and Aetna routinely consider each other's prices and formularies when setting prices and coverage amounts for their plans. This price competition between CVS and Aetna drives them to lower premiums, copayments, coinsurance, and deductibles.
Notice is hereby given pursuant to the Antitrust Procedures and Penalties Act, 15 U.S.C. 16(b)-(h), that a proposed Final Judgment, Stipulation, and Competitive Impact Statement have been filed with the United States District Court for the District of Columbia in United States of America v. CVS Health Corporation and Aetna Inc., Civil Action No. 1:18-cv-02340. On October 10, 2018, the United States filed a Complaint alleging that CVS Health Corporation's proposed acquisition of Aetna Inc. would violate Section 7 of the Clayton Act, 15 U.S.C. 18. The proposed Final Judgment, filed at the same time as the Complaint, requires the merging parties to divest Aetna's individual prescription drug plan business.
In March 2024, CVS agreed to resolve 27 Ohio Board of Pharmacy cases involving inspections of 22 stores from 2020–2023. The agreement included a $1.25 million penalty, three-year enhanced monitoring of eight stores funded by an additional $250,000, and voluntary compliance with proposed safety rules. CVS called the allegations years old; inspectors cited understaffing and other safety concerns.
The 27 cases alleged numerous safety concerns and potential legal violations found during a series of inspections of those stores between 2020 and 2023, and found that understaffing contributed significantly to many of the issues. Inspectors identified insufficient staff for the volume of prescriptions, dispensing errors, prescription delays, dirty equipment, trash throughout the pharmacies, expired medications, poor drug security and failure to report losses of controlled substances, among other issues.
In a March 2026 interview, CVS Health/Aetna executive Parsons said the company would not use AI to make adverse decisions on cases. He described ambient AI as a way to draft clinical notes and return clinicians’ attention to patients, while acknowledging that governance, payment models and the appropriate uses of AI remain unsettled.
Any honest quality conversation also has to confront fraud and mismatch between billed and delivered care, because it poisons trust for everyone. Parsons’ team actively investigates cases where services are billed but not provided. That reality is uncomfortable but ignoring it undermines the clinicians who are doing the work right.
“The company has taken a very hard stance,” he said. “AI will not ever be used to make an adverse decision on a case.”
In January 2023, CVS said it planned to seek FDA certification to dispense mifepristone where legally permitted, alongside Walgreens. The chains gave no launch timing or details on locations or mail-order availability and said they would follow state restrictions. Anti-abortion groups announced protests and a boycott in response.
Protests outside of CVS and Walgreens stores will coincide with a call-in campaign and planned national boycott of the companies after they announced they would stock and dispense abortion pills in states where they’re legal. | Drew Angerer/Getty Images
Walgreens Boots Alliance and CVS Health plan to seek U.S. certification to dispense the abortion pill, moves that could dramatically widen access to thousands of pharmacies in the parts of the country where abortion remains legal. The U.S. Food and Drug Administration has been under pressure to loosen decades-old restrictions on abortion pills, which until recently could only be distributed in healthcare settings such as doctor’s offices or hospitals. The move this week means brick-and-mortar pharmacies will be able to dispense the pills for the first time, pending a certification not required for most drugs. “This news confirms what we have said all along, this medication can and should be treated the same as other FDA-approved medications,” Kirsten Moore, director of the Expanding Medication Abortion Access Project, said. Rite Aid is still reviewing the FDA’s recent action and remains committed to complying with federal and state law, a spokesperson said in an email. Challenges persist The quick announcements on Wednesday from Walgreens and CVS, the nation’s biggest pharmacy chains, were a surprise to some experts, who had expected the decision might take longer. After Walgreens said it would pursue certification, Greer Donley, associate professor at the University of Pittsburgh School of Law who specializes in abortion policy, said other companies might “wait to see how significant the backlash is, if there is any.” There wasn’t much financial incentive for pharmacies to do so for a drug “that’s unlikely to make that much money and that has the potential to really cause them a lot of problems,” Donley added. Companies will still have to navigate a patchwork of thorny state laws that continue to prevent some patients from getting their hands on the pill despite the FDA moving to ease access. Allowing pharmacies to dispense the drug “doesn’t do a lot for expanding access dramatically in the banned states,” said Elizabeth Nash, principal policy associate for states issues with the Guttmacher Institute, an abortion research group. Some states have added specific restrictions that curtail access to medication abortions. Arizona, Texas and Arkansas, for example, ban people from getting the pill by mail. At least seven states introduced legislation last year that, if passed, would bar medication
Gunna Kristofersdottir sued CVS in January 2024, alleging it fired her for refusing on religious grounds to prescribe contraceptives. Her complaint says CVS ended her accommodation and rejected alternatives. CVS said pregnancy-prevention services are essential to the role and that it considers accommodation requests unless they pose undue hardship; it declined to discuss pending litigation.
Kristofersdottir, a devout Catholic, has requested a religious accommodation from CVS since 2014 that excludes her from having to prescribe contraceptives, which go against her religious beliefs, according to the complaint. In August 2021, CVS announced that all nurses must provide “treatment for pregnancy prevention” and removed any possibility of exemptions. (RELATED: Church Sues To Protect Homeless Ministry After City Officials Threaten Criminal Charges)
CVS Health announced plans to separate its retail pharmacies, MinuteClinics and mail-order operation into a company called CVS Pharmacy, while keeping Aetna, Caremark and senior and home-care businesses together as CVS Health. The separation is expected in the first half of 2028 and is subject to regulatory approval; it has not yet been completed.
In a breakup planned for 2028, CVS Health intends to keep together its insurance and pharmacy benefits divisions and create a separate company for its pharmacies.
CVS Health announced Wednesday that it will divide its operations into two distinct companies. The first business will contain over 9,000 drugstores, nearly 1,000 MinuteClinic retail health clinics, and a mail-order operation. This entity will be named CVS Pharmacy and led by Prem Shah. A second company will house Aetna, Caremark, Oak Street Health, and Signify Health, operating temporarily under the CVS Health name and run by David Joyner. This corporate separation is expected to conclude in the first half of 2028, pending regulatory approvals. Concurrently, CVS reported third-quarter net income of $2.17 billion on total revenues of $108.4 billion.
CVS said it will require third-party testing of supplements. The pharmacy chain had 1,400 supplements verified for the accuracy of their listed ingredients, but the source cautions that ingredient verification does not establish that the products are effective.
The pharmacy chain had 1,400 supplements verified to ensure the accuracy of listed ingredients–but that doesn’t necessarily mean the products are effective.
The Human Rights Campaign profile lists CVS Health at 50/50 for inclusive benefits, with “No Penalty” shown, and 5/5 for workforce protections. The supplied profile excerpts do not identify a date or provide additional details about the scoring.
OpenSecrets’ 2026 federal-lobbying page, updated July 23, reports $7.66 million in total CVS Health spending, including $7.48 million directly and $180,000 through subsidiaries. The page separately lists $8.745 million reported across 29 filings, reflecting a distinct total measure on the site.
In July 2015, the United States reached a civil settlement with CVS Health concerning alleged federal drug-regulation violations at its Carver pharmacy. DEA investigators found recordkeeping discrepancies affecting hundreds of Schedule II pills. CVS reported one 2014 robbery promptly but waited three weeks to report another.
Twice in the spring of 2014 armed robbers stole large quantities of Schedule II prescription drugs from the CVS pharmacy in Carver. Federal law required CVS to report the thefts immediately to the Drug Enforcement (DEA). CVS reported one of the thefts immediately but waited three weeks to report the other one.
On Jan. 30, 2024, Bloomberg Law reported that a federal court in Rhode Island allowed two former CVS Health Solutions quality-assurance consultants to proceed with a proposed class action. They allege CVS fired them because they were Black and favored South Asian employees, including in layoff decisions; CVS had sought dismissal.
Plaintiffs tested medical recordkeeping systems for CVS. They are seeking damages under Title VII, alleging CVS favored South Asian employees over Black employees in various ways including in deciding who would be laid off. They are also seeking certification of a class action
CVS Health said it planned to offer next-day delivery of prescription drugs and some over-the-counter products nationwide, likely early the following year. The company also planned same-day service in some major cities, beginning in New York City on Dec. 4 and expanding to other named cities.
CVS Health said yesterday it’s going to offer next-day delivery of prescription drugs and some over-the-counter products to the entire country, most likely early next year. The company is also starting same-day service in some big cities. The service will launch on December 4 in New York City, and expand to Miami, Boston, Philadelphia, Washington, D.C., and San […]
A lawsuit alleged CVS shared website and app user data with advertising company Criteo in violation of law. CVS and Criteo denied wrongdoing; CVS said its practices comply with applicable laws and it settled to avoid litigation costs and distraction. As of Sept. 23, 2026, final approval was pending; eligible customers could seek up to $10.
The settlement stems from a lawsuit that alleged CVS violated laws by sharing user data from its website and application with advertising company Criteo.
In its Aug. 25, 2003 announcement, the Human Rights Campaign said Aetna Inc. was among 21 companies scoring 100 percent on its Corporate Equality Index, which measures how major U.S. companies treat gay, lesbian, bisexual and transgender employees and consumers.
The Human Rights Campaign today released its second annual Corporate Equality Index, which measures how the largest U.S. companies treat their gay, lesbian, bisexual and transgender employees and consumers...The 21 companies that scored 100 percent are: Aetna Inc.; American Airlines (AMR Corp.); Apple Computer Inc.; Avaya Inc.; Bank One Corp.; Capital One Financial Corp.; Eastman Kodak Co.; Hewlett-Packard Co.; IBM Corp.; Intel Corp.; J.P. Morgan Chase & Co.; Lehman Brothers Holdings Inc.; Levi Strauss & Co.; Lucent Technologies Inc.; MetLife Inc.; NCR Corp.; Nike Inc.; PG&E Corp.; Prudential Financial Inc.; S.C. Johnson; and Xerox Corp.
Federal Election Commission records show the CVS Health PAC, a qualified corporation PAC, reported $1,562,051.88 in receipts and $1,657,082.89 in disbursements for the two-year period ending October 14, 2026. The FEC summary lists $990,000 in contributions to other committees and no independent expenditures.
OpenSecrets records CVS Health as the filer of federal lobbying reports, including reported spending of $3.57 million and $110,000 in separate entries. The records list contacts with federal agencies and Congress and bills covering health, insurance, pharmacy, labor, tax and other topics; they also show $3.32 million in another reported amount.
Fast Company reported that CVS, Walmart and Target teamed up on an effort to reinvent single-use plastic bags. The supplied report gives no further details about the initiative or its results.
Walmart, Target, and CVS team up to reinvent single-use plastic bags
Sarah Smith, a former CVS director of Enterprise Resiliency, filed suit in the U.S. District Court for the Northern District of Illinois, reported December 17, 2024. She alleges gender discrimination and retaliation, including disparate treatment, heightened scrutiny and a hostile work environment, and says CVS failed to act on her complaints. The supplied report does not give an outcome.
Smith claims that throughout her employment she was subjected to disparate treatment, higher scrutiny, and a hostile work environment compared to male colleagues. She alleges CVS failed to take corrective action when she reported discriminatory behavior and retaliation from her superiors. Smith asserts she ...
Fast Company reported that CVS Health wants to address chronic diseases through a new retail concept that would recast the local pharmacy as an assistant, educator, physician and fitness instructor. The supplied text describes the concept as a company plan and gives no launch date or outcome.
CVS Health wants to tackle chronic diseases with a new retail concept that reimagines your local pharmacy as an assistant, educator, physician, and fitness instructor.
A Pennsylvania federal judge ruled that hospitals participating in the 340B drug program are not required to contract with CVS as their third-party administrator and may choose Walgreens or other participating pharmacies, according to a March 4, 2026 report. The proposed class action had alleged CVS forced hospitals to use its administrator to obtain savings.
By Gina Kim ( March 4, 2026, 10:52 PM EST) -- CVS Health Corp. permanently defeated a proposed antitrust class action alleging it forced hospitals in a discount drug program to use its third-party administrator for savings, when a Pennsylvania federal judge ruled Tuesday that hospitals aren't required to contract with CVS and can pick Walgreens or other participating pharmacies to contract with....
OpenSecrets’ supplied figures report CVS-related lobbying of $12.476 million in 2023 and $9.46 million in 2024. For the 2024 cycle, it lists $2,954,932 in political contributions and spending, including $1,557,000 from organizations and $1,397,952 from individuals. The page says figures include affiliates’ contributions and spending.
A Fast Company headline says IBM and CVS Health believe big data can help people become healthier. The supplied evidence does not describe a specific project, timing, or outcome.
IBM and CVS Health think big data will help make you healthier.
An individual filed an NLRB charge against CVS Health in Bloomington, Minnesota, on April 21, 2025, alleging discharge, discipline and retaliation related to protected concerted activity. The case docket records a dismissal letter issued by the NLRB on July 18, 2025; the listed case status is closed.